New Anti-Obesity Pill Shows Promise With Fewer Side Effects
What Happened
An experimental daily anti-obesity pill called CRB-913 showed an average 5% weight loss in 12 weeks in early-stage testing. Unlike GLP-1 drugs such as Ozempic and Wegovy, the pill targets a different appetite-regulating receptor and reportedly caused fewer stomach-related side effects in the initial trial.
Key Takeaways
The results suggest CRB-913 could emerge as a convenient oral alternative to current weight-loss treatments, potentially offering meaningful weight reduction with better tolerability. However, researchers and doctors caution that larger, longer-term clinical trials are still needed to confirm its safety and effectiveness.